Regenerative medicine on the Gold Coast is increasingly being considered by patients looking for alternatives to repeated corticosteroid injections, long-term pain medication or surgery.
The term, however, is used very broadly. It can describe treatments with a substantial clinical evidence base, emerging biological therapies with promising but incomplete research, and experimental applications supported mainly by early studies or case reports.
Regenerative medicine should not begin with an injection. It should begin with an accurate diagnosis, an assessment of whether the affected tissue remains capable of healing and a clear explanation of the evidence supporting the proposed treatment.
At MBR Health, regenerative medicine is integrated with advanced diagnostic imaging and image-guided procedures. This allows the pathology to be assessed before treatment and, where treatment is appropriate, the biological product to be delivered accurately to the intended structure.
What is regenerative medicine?
Regenerative medicine uses biological treatments to influence inflammation, tissue repair and recovery.
In musculoskeletal medicine, commonly discussed treatments include:
- platelet-rich plasma, or PRP;
- bone marrow aspirate concentrate, or BMAC;
- stem cell treatments
- selected autologous cellular therapies;
- platelet-derived preparations;
- biological scaffolds and surgical adjuncts.
Platelets and other blood-derived components contain growth factors, cytokines and signalling molecules involved in inflammation, cell migration, angiogenesis and tissue repair.[1]
Hyaluronic acid is also commonly offered within regenerative medicine clinics. It is not a cellular therapy, but it may improve joint lubrication, shock absorption and function in selected patients with osteoarthritis.
Corticosteroid injections, nerve blocks and radiofrequency treatments are targeted pain procedures rather than regenerative therapies. They may still be clinically appropriate, but their purpose and mechanism are different.
Evidence exists on a scale
Evidence-based medicine does not divide every treatment neatly into either proven or disproven.
Clinical evidence exists on a continuum. A treatment may be supported by:
- multiple high-quality randomised controlled trials;
- systematic reviews and clinical guidelines;
- several promising but inconsistent clinical studies;
- observational studies;
- case series or individual case reports;
- laboratory or animal evidence only.
The strength of evidence may also vary significantly between conditions.
PRP may have reasonable clinical support for one condition but limited evidence for another. BMAC may have a plausible biological rationale and encouraging early results without yet having the same level of clinical evidence. An experimental pulmonary or neurological application may currently be supported only by case reports or early-stage research.
This is why it is misleading to say simply that regenerative medicine “works” or “does not work”.
The more useful question is:
Does this particular biological treatment, at this dose, delivered to this tissue, have evidence for this patient’s condition?
A responsible regenerative medicine clinic should explain where a proposed treatment sits on the evidence scale and whether it should be regarded as established, emerging or investigational.
Is regenerative medicine evidence-based?
Some regenerative treatments are supported by substantially more evidence than others.
PRP has the most developed clinical evidence among point-of-care biological treatments, particularly for knee osteoarthritis and selected chronic tendon and soft-tissue conditions.[2,3]
However, PRP is not a single standardised product. Preparations can differ in:
- platelet concentration;
- total platelet dose;
- injected volume;
- leukocyte composition;
- red-cell contamination;
- processing method;
- activation;
- number of treatments.
These differences may affect clinical outcomes. Researchers have therefore called for platelet dose, cellular composition and treatment volume to be measured and reported rather than describing every blood-derived preparation simply as PRP.[2,4]
The evidence for BMAC and other cellular treatments remains less mature and more variable. They may have a role in carefully selected patients, but they should not be presented as proven stem-cell cures or as treatments that reliably regrow cartilage.[3]
Evidence must also be considered for the specific condition being treated. Research supporting PRP for knee osteoarthritis cannot automatically be applied to a spinal disc, tendon rupture, nerve injury or neurological disorder.
Regenerative treatments considered on the Gold Coast
Platelet-rich plasma
PRP is prepared from the patient’s own blood. The blood is processed to concentrate platelets and selected plasma and cellular components before being delivered to the treatment target. The relevant question is not simply whether the treatment is called PRP. Platelet concentration, treatment volume and total platelet dose all matter.[2,4]
At MBR Health, platelet concentration is measured using a dedicated platelet counter so the delivered platelet dose can be documented rather than assumed.
For more detailed information, see:
- What Is PRP Therapy and How Does It Work?
- Not All PRP is the Same: Why Platelet Dose (High-Dose PRP) Matters
- PRP for Knee Osteoarthritis: Evidence, Dose, Candidates, and Can It Delay Knee Replacement?
- Treating Spinal Pain with PRP and Biological Therapies
- Why PRP May Not have Worked
- Nebulised PRP for Lung Disease: What Patients Should Know
Bone marrow aspirate concentrate
BMAC is prepared by collecting bone marrow, usually from the pelvis, and concentrating selected components.
It contains a mixture of:
- plasma;
- platelets;
- white blood cells;
- mononuclear cells;
- haematopoietic cells;
- a relatively small population of stromal or progenitor cells.
BMAC is sometimes promoted as stem-cell therapy, but this description is incomplete and may be misleading.
BMAC is not a purified or culture-expanded stem-cell product. Its cellular composition can vary considerably between patients and preparation systems.
Clinical evidence for BMAC remains in development. It may be considered in selected complex musculoskeletal conditions, but patients should receive a balanced explanation of the evidence, limitations, uncertainties and available alternatives.[3]
BMAC and other human cell or tissue therapies must be used within strict Therapeutic Goods Administration regulatory requirements. Their lawful use depends on factors including the source material, preparation method, degree of manipulation, intended clinical function, treatment setting and applicable regulatory pathway. BMAC may therefore not be legally or clinically applicable for every proposed condition or treatment application.
The fact that a product is autologous—meaning that it comes from the same patient—does not automatically mean that it is approved, exempt from regulation or proven effective.
Hyaluronic acid
Hyaluronic acid is naturally present in joint fluid and contributes to lubrication and shock absorption.
High-molecular-weight, cross-linked hyaluronic acid may be used in selected osteoarthritic joints. It can be administered alone or, in some clinical pathways, alongside PRP.
Clinical outcomes vary according to factors including:
- the joint being treated;
- osteoarthritis severity;
- product formulation;
- inflammatory activity;
- joint mechanics;
- patient characteristics.[5]
Hyaluronic acid is not a cellular regenerative therapy, but it may support the mechanical environment of the joint and form part of a broader treatment pathway.
What conditions may be considered?
Regenerative treatments may be considered in selected patients with:
- knee osteoarthritis;
- hip osteoarthritis;
- shoulder and rotator-cuff pathology;
- tennis elbow;
- plantar fasciitis;
- Achilles and patellar tendinopathy;
- hamstring and gluteal tendon injuries;
- selected pulmonary issues
- ligament injuries;
- anterior cruciate ligament tears or ruptures;
- sports injuries;
- selected spinal pain conditions;
- sacroiliac-joint pain;
- selected peripheral nerve injuries;
- selected infections
- persistent post-surgical musculoskeletal pain.
Being included on this list does not mean regenerative treatment is suitable or supported by the same level of evidence for every presentation.
A degenerative tendon, a small partial tear and a complete retracted tendon rupture are different clinical problems. Similarly, early osteoarthritis and end-stage joint destruction require different treatment discussions.
Condition-specific assessment and imaging are therefore essential.
Separate articles on MBR Health examine the evidence and treatment considerations for individual conditions in greater detail.
Why diagnosis matters
Pain does not always arise from the most obvious abnormality on a scan.
Back pain, for example, may arise from:
- an intervertebral disc;
- a facet joint;
- the sacroiliac joint;
- a nerve root;
- muscle or connective tissue;
- another referred source.
Shoulder pain may reflect:
- bursitis;
- tendinopathy;
- partial or complete tendon tearing;
- arthritis;
- instability;
- nerve-related or referred pain.
A biological treatment is unlikely to produce a reliable result when the diagnosis or treatment target is incorrect.
The first question should therefore not be which injection to use. It should be which structure is causing the symptoms and whether that structure is biologically and mechanically capable of healing.
Why image guidance matters
A well-prepared biological product still needs to reach the intended tissue.
Image guidance may be performed with:
- ultrasound for many joints, tendons, bursae and superficial nerves;
- CT for deep joints, spinal structures, intervertebral discs and anatomically complex targets.
Neither modality is universally superior.
Ultrasound provides real-time imaging without radiation and is highly effective for many superficial and moderately deep targets.
CT provides a larger field of view and detailed visualisation of bone, deep anatomy and complex spinal structures. It may also document final needle position and, where necessary, the distribution of injected contrast.
The appropriate guidance method depends on the structure being treated.
What does autologous mean?
Most point-of-care regenerative treatments used in Australian private medical practice are autologous.
Autologous means that blood, cells or tissue are collected from and returned to the same patient.
Examples include:
- PRP prepared from the patient’s blood;
- BMAC prepared from the patient’s bone marrow;
- selected autologous grafts and cellular preparations.
Autologous does not mean that a treatment is automatically approved, proven or free of risk.
It describes where the biological material came from. It does not establish whether the product is effective or legally available for the proposed condition.[6]
Stem-cell and cellular therapy limitations in Australia
Human cell and tissue therapies are regulated in Australia according to:
- the source of the material;
- how it is processed;
- the degree to which it is manipulated;
- where it is manufactured;
- its intended clinical function;
- how it is supplied and advertised.
Some point-of-care autologous products may qualify for regulatory exemptions when strict criteria are met. These may include appropriate medical supervision, minimal manipulation, homologous use and use within a single clinical procedure.[6,7]
Homologous use generally means that the cells or tissues are intended to perform the same basic function after treatment as they performed in their original location.
Products that are culture-expanded, substantially manipulated, donor-derived or intended to perform a different biological function may require another regulatory pathway. This may include:
- inclusion in the Australian Register of Therapeutic Goods;
- use within an eligible clinical trial;
- the Special Access Scheme;
- the Authorised Prescriber pathway;
- an applicable hospital or regulatory framework.
Australia does not prohibit all non-autologous cellular therapies. However, private clinics cannot simply manufacture or provide culture-expanded or donor-derived stem-cell products without an appropriate lawful pathway.
A treatment being described as TGA exempt is also not the same as the TGA having assessed and approved its effectiveness for a particular condition.[6-8]
The MBR Health approach
Regenerative medicine at MBR Health is based on four principles.
The purpose of the initial assessment is not to assume that every patient requires PRP, BMAC or another injectable treatment.
It is to determine:
- what is causing the symptoms;
- whether the tissue remains capable of healing;
- where the proposed treatment sits on the evidence scale;
- whether conventional treatment remains preferable;
- whether the treatment is clinically and legally available;
- whether the application is established, emerging or investigational.
Any cellular therapy must also be considered within the applicable Australian regulatory framework. A therapy may have a plausible biological rationale without necessarily being legally available, clinically appropriate or adequately supported for every indication.
Who may not be suitable?
Regenerative treatment may not be appropriate where there is:
- an uncertain diagnosis;
- active metastasis or infection;
- significant bleeding risk;
- severe platelet or blood-count abnormality;
- mechanically irreparable tissue;
- advanced joint destruction;
- untreated instability;
- a condition requiring urgent surgery;
- inability to participate in rehabilitation;
- unrealistic treatment expectations.
Suitability must be determined individually.
Regenerative medicine should remain medicine
Regenerative medicine offers meaningful treatment options for selected patients, but it should not be built around vague promises of healing or stem-cell regeneration.
A credible regenerative medicine clinic should be able to explain:
1. the diagnosis;
2. the biological product being delivered;
3. the dose and composition;
4. the method of image-guided delivery and patient record of final location;
5. the quality of evidence for that specific condition;
6. where the treatment sits on the evidence scale;
7. whether it is established, emerging or investigational;
8. whether it is available under the applicable Australian regulatory pathway.
The future of regenerative medicine will be defined not by the number of treatments offered, but by accurate diagnosis, transparent biological measurement, precise delivery, regulatory compliance and the honest evaluation of clinical outcomes.
Author: Dr Kirralee Sherif (PhD)
Frequently Asked Questions
Below are some frequently asked questions related to this article, if you have any other questions please visit our FAQs page.
What is regenerative medicine?
Regenerative medicine uses biological treatments to influence inflammation, tissue repair and recovery. Common examples include PRP and selected autologous biological therapies.
Is all regenerative medicine supported by the same evidence?
No. Evidence exists on a continuum. Some applications are supported by randomised trials and clinical guidelines, while others rely on early studies, case reports or laboratory research.
Is PRP a stem-cell treatment?
No. PRP is prepared from blood and contains concentrated platelets, plasma and selected cellular components. It is not a stem-cell treatment.
Is BMAC stem-cell therapy?
BMAC contains a mixed population of bone-marrow-derived components, including a relatively small number of stromal or progenitor cells. It is not a purified or culture-expanded stem-cell product.
Is BMAC available for every condition?
No. BMAC must be used within strict TGA regulatory requirements. Its lawful and appropriate use depends on the product, processing, intended function, treatment setting and applicable regulatory pathway. It may not be available or suitable for some applications.
Are stem-cell treatments legal in Australia?
Some cellular therapies are legally available through specific regulatory pathways. Autologous point-of-care products may qualify for exemptions when strict criteria are satisfied. Other products may require ARTG inclusion, clinical-trial access or another approved pathway.
Does TGA exemption mean a treatment is approved?
No. Exemption from certain regulatory requirements does not mean that the TGA has evaluated and approved the treatment as safe and effective for a particular condition.
Where is regenerative medicine available on the Gold Coast?
MBR Health provides diagnosis-led, image-guided regenerative medicine assessments at Mermaid Beach on the Gold Coast. Treatment suitability, evidence and regulatory availability are considered individually.
References
- Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regen Med. 2013 Sep;8(5):645-58. doi: 10.2217/rme.13.59. PMID: 23998756.
- Mautner K, Malanga GA, Smith J, et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM R. 2015;7(4 Suppl):S53-S59. doi:10.1016/j.pmrj.2015.02.005.
- D’Souza RS, Her YF, Hussain N, Karri J, Schatman ME, Calodney AK, Lam C, Buchheit T, Boettcher BJ, Chang Chien GC, Pritzlaff SG, Centeno C, Shapiro SA, Klasova J, Grider JS, Hubbard R, Ege E, Johnson S, Epstein MH, Kubrova E, Ramadan ME, Moreira AM, Vardhan S, Eshraghi Y, Javed S, Abdullah NM, Christo PJ, Diwan S, Hassett LC, Sayed D, Deer TR. Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group. J Pain Res. 2024 Sep 11;17:2951-3001. doi: 10.2147/JPR.S480559. PMID: 39282657; PMCID: PMC11402349.
- Berrigan W, Tao F, Kopcow J, Park AL, Allen I, Tahir P, Reddy A, Bailowitz Z. The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Curr Rev Musculoskelet Med. 2024 Dec;17(12):570-588. doi: 10.1007/s12178-024-09922-x. Epub 2024 Sep 27. PMID: 39331322; PMCID: PMC11652557.
- Conrozier T, Raman R, Diraçoglu D, Montfort J, Bard H, Baron D, Goncalves B, Richette P, Migliore A, Chevalier X, Brittberg M, Henrotin Y. EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics. Cartilage. 2025 Dec;16(4):438-452. doi: 10.1177/19476035241271970. Epub 2024 Nov 20. PMID: 39564753; PMCID: PMC11577334..
- Therapeutic Goods Administration. Understanding regulation of autologous human cell and tissue products. Australian Government Department of Health and Aged Care.
- Therapeutic Goods Administration. Manufacturing exempt autologous human cell and tissue products. Australian Government Department of Health and Aged Care. Updated 3 October 2024.
- Therapeutic Goods Administration. Stem cell treatments and regulation: a quick guide for consumers. Australian Government Department of Health and Aged Care.
Medical and regulatory disclaimer
This article provides general health and regulatory information and does not constitute individual medical or legal advice.
The regulatory status of BMAC and other human cell or tissue therapies depends on the source material, preparation method, degree of manipulation, intended function, clinical setting and supply pathway. These treatments must be used within applicable TGA, professional and clinical-governance requirements and may not be legally available, clinically appropriate or evidence-supported for every proposed application.
Some regenerative treatments remain emerging or investigational.
